Manufacturing Facility Updates
PharmaTech
APRIL 1, 2024
Pharmaceutical Technology gives a brief overview of some of developments in manufacturing facilities, including news from W.R. Grace & Co, ITT Inc, and SMC.
technology-overview 
Mixing Technologies in the Pharmaceutical and Medical Industries (May 2024)
PharmaTech
MAY 13, 2024
This white paper presents an overview of mixing technologies implemented across many of today’s highly competitive pharmaceutical and medical industries, as well as new equipment designs that are increasingly being recognized as potential solutions to prevailing mixing challenges.
52 Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
AI presents obstacles and opportunities in pharma: Iqvia
Outsourcing Pharma
SEPTEMBER 16, 2020
A leader from Iqvia will present an overview of artificial intelligence, machine learning and other technology during this yearâs CPhI Festival of Pharma.
72 
Analytica 2024 in overview
European Pharmaceutical Review
MARCH 5, 2024
Pharmaceutical analytics is considered a cross-cutting technology that ensures product quality and economic success. analytica 2024 provides a comprehensive overview of innovative analytics and molecular – as well as microbiological – testing methods. For further information, visit: analytica.de/en/munich
Labelling 86
86 Labelling 86
86 
Health Innovators – Dr. Houda Hachad
pharmaphorum
SEPTEMBER 30, 2022
And that same technology and approach can also be of benefit to other chronic conditions, from cardiovascular disease to behavioural health. Tune in for an insightful overview of precision medicine and its many possibilities. Houda has spent her career studying the ways that genetic testing can change our whole approach to medicine.
97 
Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 23, 2023
Ranibizumab biosimilar overview Ranibizumab biosimilar is under development for the treatment of neovascular (wet) age-related macular degeneration. Generium overview Generium is a pharmaceutical company developing novel biological drugs for the treatment of orphan diseases. Generium is headquartered in Moscow, Russia.
Biosimilars 52
52 
PHARMAP 2024 held in Amsterdam, marks its fourth edition
Express Pharma
MAY 6, 2024
In an overview, the event comprised a business programme packed with sessions, roundtables and panel discussions. The second day started off with a panel discussion sponsored by Systech, where delegates debated serialisation and track-and-trace technologies in the pharmaceutical packaging sector. and Produlab Pharma.
Packaging 98
98 
KFA-115 by Novartis for Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 overview KFA-115 is under development for the treatment of hematological tumor and melanoma, renal cell carcinoma, ovarian cancer, nasopharyngeal cancer, thymic carcinoma, anal cancer, malignant mesothelioma, esophageal cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer.
Technology and Human Care Combine to Support the Medication Access Journey
Drug Channels
JUNE 4, 2021
Nathan discusses how technology can augment human expertise to help people access, afford, and adhere to their medications. To learn more, download CoverMyMeds’ new solutions overview: Technology Helps Drive Medication Access, Adherence and Affordability. Today’s guest post comes from Nathan Mott, President of CoverMyMeds.
52 
QN-023a by Hangzhou Qihan Biotechnology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
MARCH 2, 2023
QN-023a overview QN-023a is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML). Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company. The company develops gene-editing organ transplantation technology.
(LAI-287 + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
(LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes. The post (LAI-287 + semaglutide) by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval appeared first on Pharmaceutical Technology.
Diabetes 72
72 
Powering a US dietary supplements acquisition
Fuld & Company Blog
FEBRUARY 7, 2024
This provided a comprehensive overview of the factors influencing the dietary supplements market capturing the headwind and tailwind, technology, buyers shifting demographics, and buying behaviors. This provided a comprehensive overview of competitor activities to support the firm’s acquisition decision.
52 
QN-019a by Hangzhou Qihan Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Pharmaceutical Technology
MARCH 2, 2023
QN-019a overview QN-019a is under development for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company. The company develops gene-editing organ transplantation technology.
Preserving Trusted Brand Prescribing Through the Patient Journey
Drug Channels
JANUARY 8, 2021
She describes CoverMyMeds’ technology solutions that are designed to help patients access, afford, and adhere to their prescribed medications. To learn more about CoverMyMeds’ medication access solutions, download their Technology Solutions Overview. Julia discusses common patient access and affordability issues.
52 
Newsletter – October 2023
Fuld & Company Blog
OCTOBER 9, 2023
Plus, our Technology & Innovation Research team highlights innovative CO2 reduction strategies, spotlighting initiatives by global frontrunners. Discover how AI is amplifying human capabilities in the Private Equity world, navigating its ever-evolving landscape. I trust you’ll find these insights valuable.
ASP-1570 by Astellas Pharma for Metastatic Melanoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-1570 overview ASP-1570 is under development for the treatment of advanced solid tumors including metastatic melanoma and non-small cell lung carcinoma (NSCLC). Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals.
ASP-1570 by Astellas Pharma for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-1570 overview ASP-1570 is under development for the treatment of advanced solid tumors including metastatic melanoma and non-small cell lung carcinoma (NSCLC). Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals.
Kid EDV by ImmunityBio for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Kid EDV overview Kid EDV is under development for the treatment of recurrent or refractory solid or CNS tumors including diffuse intrinsic pontine gliomas of children. It is developed based on EDV nanocell technology. It is administered intravenously. The therapeutic candidate acts by targeting EGFR expressing cancer cells.
Immunity 52
52 
Hydrocortisone by Antares Pharma for Adrenal Insufficiency: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 27, 2023
Hydrocortisone overview Hydrocortisone (ATRS-1902) is under development for the treatment of adrenal crisis rescue. Antares Pharma overview Antares Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies.
ASP-2138 by Xencor for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 overview ASP-2138 is under development for the treatment of adenocarcinoma of the gastroesophageal junction, metastatic pancreatic adenocarcinoma and gastric cancer. The drug candidate is being developed based on XmAb technology. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2
Immunity 40
40 
ASP-2138 by Xencor for Gastric Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 overview ASP-2138 is under development for the treatment of adenocarcinoma of the gastroesophageal junction, metastatic pancreatic adenocarcinoma and gastric cancer. The drug candidate is being developed based on XmAb technology. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2
Immunity 40
40 
ASP-2138 by Xencor for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-2138 overview ASP-2138 is under development for the treatment of adenocarcinoma of the gastroesophageal junction, metastatic pancreatic adenocarcinoma and gastric cancer. The drug candidate is being developed based on XmAb technology. The therapeutic candidate is a bispecific antibody targeting CD3 and claudin 18.2
Immunity 40
40 
NPT-2042 by NeuroPro Therapeutics for Seizures: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
NPT-2042 overview NPT-2042 is under development as an adjunct anti seizure treatment for patients with medically intractable epilepsy. NeuroPro Therapeutics overview NeuroPro Therapeutics is a North Carolina-based stealth biotechnology company. It is administered as soft-gelatin capsules administered through orally route.
Amlitelimab by Kymab for Asthma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
Amlitelimab overview Amlitelimab (KY-1005) is under development for the treatment of graft-versus-host disease, mild-to-moderate psoriasis, atopic dermatitis, asthma and other immune mediated disease. It is developed based on Kymouse technology. It is administered through intravenous and subcutaneous routes as an infusion.
Immunity 40
40 
Lefitolimod by Mologen for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 22, 2023
Lefitolimod overview MGN-1703 (lefitolimod) is under development for the treatment of solid tumors, small cell lung cancer and chronic HIV-1 Infection. The drug candidate is based on dSLIM (double stem-loop immunomodulator) technology platform. The drug candidate is based on dSLIM (double stem-loop immunomodulator) technology platform.
Immunity 40
40 
XNW-4107 by Evopoint Bioscience for Ventilator Associated Pneumonia (VAP): Likelihood of Approval
Pharmaceutical Technology
MARCH 4, 2023
XNW-4107 overview XNW-4107 is under development for the treatment of Gram-negative bacterial infections, urinary tract infections, hospital acquired and ventilator associated pneumonia. The post XNW-4107 by Evopoint Bioscience for Ventilator Associated Pneumonia (VAP): Likelihood of Approval appeared first on Pharmaceutical Technology.
Hospitals 40
40 HY-0102 by Shanghai HyaMab Biotech for Head And Neck Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 27, 2023
HY-0102 overview HY-0102 is under development for the treatment of locally advanced and metastatic solid tumors including head and neck cancer, liver cancer, colorectal cancer, lung cancer. Shanghai HyaMab Biotech overview Shanghai HyaMab Biotech (HyaMab Biotech) is a biotech company focusing on treatment of cancers and autoimmune diseases.
GI-XBI-302 by Xbiome for Graft Versus Host Disease (GVHD): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 27, 2023
GI-XBI-302 overview GI-XBI-302 is under development for the treatment of graft versus host disease (GVHD) and solid tumors. Xbiome overview Xbiome Co., The post GI-XBI-302 by Xbiome for Graft Versus Host Disease (GVHD): Likelihood of Approval appeared first on Pharmaceutical Technology. It is administered through oral route.
Executive Summary - Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules
PharmaTech
AUGUST 20, 2023
Lastly, this executive summary includes an overview of Catalent’s oral solid dose turnkey solutions featuring advanced oral solid dosage (OSD) manufacturing technologies and expertise throughout an extensive global network. In addition, the experts will explain how these approaches can facilitate in the tech transfer of a program.
Dosage 40
40 Dosage 40
40 
ASP-1570 by Astellas Pharma for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 25, 2023
ASP-1570 overview ASP-1570 is under development for the treatment of advanced solid tumors including metastatic melanoma and non-small cell lung carcinoma (NSCLC). Astellas Pharma overview Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals.
CMN-005 by CoImmune for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 22, 2023
CMN-005 overview CMN-005 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma post bone marrow transplantation. It acts by targeting the cancer cells which express CD19 antigen. The cell therapy is developed based on C.I.K.
VE-818 by Vedanta Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval
Pharmaceutical Technology
MARCH 4, 2023
VE-818 overview VE-818 is under development for the treatment of graft versus host disease (GVHD). The post VE-818 by Vedanta Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval appeared first on Pharmaceutical Technology. It is administered through oral route as capsule.
Immunity 40
40 
VE-818 by Vedanta Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval
Pharmaceutical Technology
MARCH 4, 2023
VE-818 overview VE-818 is under development for the treatment of graft versus host disease (GVHD). The post VE-818 by Vedanta Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval appeared first on Pharmaceutical Technology. It is administered through oral route as capsule.
Immunity 40
40 
RT-002 by Revance Therapeutics for Upper Limb Muscle Spasticity: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
RT-002 overview RT-002 is under development for the treatment of spasmodic torticollis (cervical dystonia), upper limb spasticity and chronic migraine. It is developed based on TransMTS peptide technology. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio.
RT-002 by Revance Therapeutics for Upper Limb Muscle Spasticity: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
RT-002 overview RT-002 is under development for the treatment of spasmodic torticollis (cervical dystonia), upper limb spasticity and chronic migraine. It is developed based on TransMTS peptide technology. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio.
AT-1412 by Kling Biotherapeutics for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 19, 2023
AT-1412 overview KBA-1412 is under development for the treatment of solid tumors, melanoma. Kling Biotherapeutics overview Kling Biotherapeutics (Kling Bio) is a biotherapeutics discovery and development company focusing on novel antibody based therapeutics. It acts by targeting cells expressing CD9 epitope.
Treprostinil SR by Camurus for Raynauds Disease: Likelihood of Approval
Pharmaceutical Technology
MARCH 4, 2023
Treprostinil SR overview Treprostinil ( CAM-2043 ) is under development for the treatment of pulmonary arterial hypertension and Raynaud’s disease secondary to systemic sclerosis. The drug candidate is a once-weekly liquid crystal gel formulation developed based on FluidCrystal injectable depot technology.
Treprostinil SR by Camurus for Raynauds Disease: Likelihood of Approval
Pharmaceutical Technology
MARCH 4, 2023
Treprostinil SR overview Treprostinil ( CAM-2043 ) is under development for the treatment of pulmonary arterial hypertension and Raynaud’s disease secondary to systemic sclerosis. The drug candidate is a once-weekly liquid crystal gel formulation developed based on FluidCrystal injectable depot technology.
Orvacabtagene autoleucel by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Orvacabtagene autoleucel overview Orvacabtagene autoleucel (ET-140) is under development for the treatment of relapsed and refractory multiple myeloma. It is developed based on chimeric antigen receptor (CAR) technology. It is chimeric antigen receptor (CAR) cell therapy. It is administered as intravenous infusion.
Hospitals 40
40 ACD-440 by AlzeCure Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
ACD-440 overview ACD-440 is under development for the treatment of neuropathic pain including painful peripheral polyneuropathy, peripheral mononeuropathy, postherpetic neuralgia (PHN), chemotherapy induced neuropathic pain, nerve injury pain, chronic postoperative neuropathic pain and peripheral neuropathic pain.
Chemotherapy 40
40 ATRN-119 by Aprea Therapeutics for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
ATRN-119 overview ATRN-119 is under development for the treatment of advanced solid tumors including ovarian cancer, endometrial cancer, cervical cancer, colon cancer, breast cancer and prostate cancer. These are developed based on Atrize platform technology. The drug candidate is administered through oral route.
Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules
PharmaTech
MAY 31, 2023
Lastly, this webinar will feature an overview of Catalent’s oral solid dose turnkey solutions featuring advanced oral solid dosage (OSD) manufacturing technologies and expertise throughout an extensive global network. In addition, the experts will explain how these approaches can facilitate in the tech transfer of a program.
Dosage 40
40 Dosage 40
40 MP-0310 by Molecular Partners for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
It is developed based on DARPin technology. Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. It also develops drugs on DARPin base technology and other product candidates.
MP-0310 by Molecular Partners for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
It is developed based on DARPin technology. Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. It also develops drugs on DARPin base technology and other product candidates.
Let's personalize your content